DUBLIN--(BUSINESS WIRE)--Aug 17, 2018--The "Diarrhea and Constipation Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering.

Diarrhea and Constipation Drug Development Pipeline Review, 2018 provides an overview of the pipeline landscape for diarrhea and constipation. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for diarrhea and constipation, and features dormant and discontinued products.

There are 54 products in development for this indication and molecular targets present in the pipeline landscape include cystic fibrosis transmembrane conductance regulator and glucagon like peptide 2 receptor.

There are 25 products in development for this indication and molecular targets present in the pipeline landscape include 5-hydroxytryptamine receptor 4 and heat stable enterotoxin receptor.

Companies operating in this pipeline space include Synthetic Biologics, Allergan and Ardelyx.


Which companies are the most active within each pipeline? Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication? To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies? What are the most important R&D milestones and data publications to have happened in this disease area?

Key Topics Covered:

1 Tables & Figures

2 Introduction

2.1 Diarrhea and Constipation Report Coverage

2.2 Constipation - Overview

2.3 Diarrhea - Overview

3 Therapeutics Development

4 Therapeutics Assessment

5 Companies Involved in Therapeutics Development

6 Dormant Projects

7 Discontinued Products

8 Product Development Milestones

9 Appendix

Companies Mentioned

Aegis Therapeutics LLC Akthelia Pharmaceuticals Ltd Albireo Pharma Inc Allergan Plc Ardelyx Inc AzurRx BioPharma Inc Bharat Biotech Ltd DiscoveryBiomed Inc Dong-A ST Co Ltd EA Pharma Co Ltd Ferring International Center SA GP Pharm SA Ironwood Pharmaceuticals Inc Johnson & Johnson Kuhnil Pharmaceutical Co Ltd MallInckrodt Plc Metacrine Inc NGM Biopharmaceuticals Inc Nippon Shinyaku Co Ltd Novartis AG Pfizer Inc Prokarium Ltd Protagonist Therapeutics Inc RaQualia Pharma Inc RedHill Biopharma Ltd RxBio Inc SK Biopharmaceuticals Co Ltd Sublimity Therapeutics Ltd Summit Therapeutics Plc Synthetic Biologics Inc Syntiron LLC Tasly Pharmaceutical Group Co Ltd Yuhan Corp Zealand Pharma AS Zensun (Shanghai) Sci & Tech Co Ltd

For more information about this report visit https://www.researchandmarkets.com/research/bg6rbp/2018_diarrhea_and?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180817005106/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery,Gastrointestinal Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/17/2018 05:39 AM/DISC: 08/17/2018 05:39 AM